FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 華檢醫療控股有限公司 呈交日期： 2025年7月25日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 01931 | 說明 | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | 庫存股份變動 | | | | | 事件 | 已發行股份（不包括庫存股份）數 目 | 佔有關事件前的現有已發 行股份（不包括庫存 ...

Core Viewpoint - The article highlights the innovative strategy of Huajian Medical (01931) in leveraging Web3 technology and real-world asset (RWA) tokenization to revolutionize the liquidity of innovative drug assets, marking a significant shift in the global financial landscape [1][2]. Group 1: Market Dynamics - The RWA market, excluding stablecoins, is projected to reach $245.5 billion by June 2025, with expectations to expand to $16.1 trillion by 2030, representing 10% of global GDP [2]. - The total market capitalization of global stablecoins has reached $263.6 billion, supported by regulatory frameworks such as the U.S. "Genius Act" and Hong Kong's "Stablecoin Regulation" [2]. Group 2: Strategic Initiatives - Huajian Medical is pursuing a dual listing in Hong Kong and the U.S. to enhance financing channels and promote capital synergy [1]. - The company aims to create a "NewCo + RWA" Web3 exchange ecosystem centered around high-tech medical innovation assets, issuing a proprietary stablecoin (IVDD) and applying for a stablecoin license in the U.S. [1][6]. Group 3: Innovative Financing Model - The RWA tokenization allows for the fragmentation and digitalization of physical assets, enabling 24/7 trading and global liquidity, which is particularly beneficial in the medical innovation sector [2][4]. - By tokenizing assets, Huajian Medical can lower investment thresholds, attracting global capital and improving financing efficiency in the innovative drug industry [4][6]. Group 4: Compliance and Regulatory Strategy - Huajian Medical's strategy includes establishing a fully owned subsidiary in New York for stablecoin license applications while participating in Hong Kong's regulatory sandbox for stablecoins [7]. - The company is developing three foundational infrastructures: an RWA tokenization platform, an IVDD stablecoin issuance and clearing system, and a "coin-stock linkage" mechanism with dual listings [7]. Group 5: Capital Market Signals - The company has executed a stock buyback of 141,000 shares at an average price of HKD 3.16 per share, signaling management's confidence in the strategic direction and market outlook [1][8]. - The IVDD stablecoin holders will have preferential rights to subscribe for Huajian Medical's shares, creating a value cycle between crypto capital and traditional equity markets [8].

Summary of Key Points Core Viewpoint - On July 23, 21 Hong Kong-listed companies conducted share buybacks, totaling 20.97 million shares and an aggregate amount of HKD 44.00 million [1][2]. Group 1: Buyback Details - VITASOY INT'L repurchased 1.402 million shares for HKD 12.98 million, with a highest price of HKD 9.260 and a lowest price of HKD 9.230, accumulating HKD 151.00 million in buybacks for the year [1][2]. - China Eastern Airlines repurchased 2.50 million shares for HKD 7.32 million, with a highest price of HKD 2.970 and a lowest price of HKD 2.900, totaling HKD 601.30 million in buybacks for the year [1][2]. - China Feihe repurchased 1.00 million shares for HKD 4.70 million, with a highest price of HKD 4.700, accumulating HKD 93.00 million in buybacks for the year [1][2]. Group 2: Buyback Rankings - The highest buyback amount on July 23 was from VITASOY INT'L at HKD 12.98 million, followed by China Eastern Airlines at HKD 7.32 million [1][2]. - In terms of share quantity, the most shares repurchased were by Shoujia Technology at 7.40 million shares, followed by China Eastern Airlines at 2.50 million shares [1][2].

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 華檢醫療控股有限公司 呈交日期： 2025年7月23日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 01931 | 說明 | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | | | | | 事件 | 已發行股份（不包括庫存股份）數 目 | 佔有關事件前的現有已發 行股份（不包括庫存 ...

Core Viewpoint - The surge in Huajian Medical's stock price is driven by its announcement to apply for stablecoin issuance licenses in Hong Kong and the U.S., positioning itself as a pioneer in the medical technology sector for stablecoin issuance [2][3][4]. Group 1: Stock Performance - On July 21, Huajian Medical's stock opened significantly higher, peaking at a 58% increase, and closed up 32.88% at HKD 3.92 per share, with a market capitalization of HKD 6.356 billion [2]. - The company experienced a cumulative stock increase of 60% over two days, with trading volume exceeding HKD 50 million [2]. Group 2: Business Developments - On July 17, Huajian Medical announced the initiation of its stablecoin issuance license application process with relevant regulatory bodies in Hong Kong and the U.S. [2][3]. - The company’s U.S. subsidiary, IVDGROUPINC., has completed its registration and is now officially starting the stablecoin license application process [3]. Group 3: Market Reactions and Analysis - The market has shown mixed reactions to Huajian Medical's cross-industry initiatives, with some skepticism regarding its motives and the potential for "storytelling" [3]. - Analysts suggest that the company's approach addresses long-standing issues in the innovative drug sector, such as low liquidity and long financing cycles, by creating a Real World Asset (RWA) exchange focused on medical innovation [3][4]. Group 4: Regulatory Environment - Recent legislative developments in Hong Kong and the U.S. provide a favorable regulatory framework for stablecoin operations, enhancing Huajian Medical's strategic positioning [4]. - The Hong Kong Legislative Council's approval of the Stablecoin Bill marks a significant regulatory milestone, establishing a comprehensive framework for stablecoins and attracting Web3 projects to the region [4]. Group 5: Future Outlook - Market sentiment indicates confidence in the "innovative drug + stablecoin" integration, with expectations that Huajian Medical's RWA ecosystem could reshape valuation logic in the medical innovation sector [5]. - The potential for the company's stock to continue rising remains a point of interest for investors as it navigates the stablecoin landscape [5].

Core Viewpoint - As of July 21, 200 stocks reached their 52-week highs, with notable performers including Dongfang Electric (681.62%), Huaxin Cement (84.42%), and Aoyuan Group Equity (80.00%) [1][2]. Summary by Category 52-Week High Performers - Dongfang Electric (01072) closed at 24.650, with a peak price of 119.900, achieving a high rate of 681.62% [2]. - Huaxin Cement (06655) closed at 18.600, with a peak price of 20.100, achieving a high rate of 84.42% [2]. - Aoyuan Group Equity (02905) closed at 0.350, with a peak price of 0.450, achieving a high rate of 80.00% [2]. - Other notable stocks include: - Zhong'an Holdings Group (08462) with a high rate of 71.05% [2]. - Huajian Medical (01931) with a high rate of 57.97% [2]. - Songjing Technology (01079) with a high rate of 44.76% [2]. Additional High Performers - China Pipe Industry (00380) reached a high rate of 43.67% [2]. - Tibet Water Resources (01115) achieved a high rate of 39.33% [2]. - China Energy Construction (03996) reached a high rate of 38.03% [2]. - Other stocks with notable high rates include: - Changsheng Group-B (06628) at 25.23% [2]. - Harbin Electric (01133) at 24.84% [2]. - Fangyuan Life Services (09978) at 22.11% [2].

Core Viewpoint - The stablecoin industry is transitioning from "concept exploration" to "compliance implementation," with a focus on regulatory clarity and the establishment of a full industry chain in the Hong Kong stock market, where nearly 20 stablecoin concept stocks are involved [1]. Group 1: Business Positioning - Hong Kong stablecoin concept stocks generally focus on cross-border payments and broad RWA applications, with a "breadth-first" business model [2]. - In contrast, Huajian Medical's IVDD stablecoin adopts a "depth-first" strategy, concentrating on high-barrier medical innovation assets, including gene therapies and targeted drugs [3]. Group 2: Technical Architecture - Most Hong Kong stablecoin concept stocks utilize a "public chain + smart contract" generic architecture [4]. - Huajian Medical's IVDD employs a "hybrid architecture + deep adaptation to medical scenarios," enhancing asset tokenization precision and efficiency [6][7]. Group 3: Compliance Pathways - Hong Kong stablecoin concept stocks exhibit a "license-driven" compliance approach, with companies like Guotai Junan International obtaining licenses to provide stablecoin trading services [8][9]. - Huajian Medical's IVDD follows a "license + ecosystem" dual-driven model, applying for a stablecoin license while building a medical data flow platform [10]. Group 4: Ecological Value - Most Hong Kong stablecoin concept stocks are positioned as "payment tools," focusing on facilitating transactions [11][12]. - Huajian Medical's IVDD aims to be a "medical industry innovator," enhancing asset liquidity and potentially transforming the medical asset value ecosystem [13]. Group 5: Future Outlook - The implementation of Hong Kong's Stablecoin Regulation and the advancement of the U.S. GENIUS Act will lead to differentiation among Hong Kong stablecoin concept stocks [14]. - Huajian Medical's IVDD, as a pioneer in medical RWA, is expected to replicate successful financing models and expand its asset management scale significantly [15][16].

Core Viewpoint - The company is actively constructing a Web3 exchange ecosystem centered around high-tech medical innovation assets, aiming to enhance liquidity, financing efficiency, and accessibility in the global medical innovation drug market [1][2]. Group 1: Strategic Developments - The company has established a wholly-owned subsidiary in New York, IVD GROUP INC., which will serve as the core operational entity for advancing the IVDNewCo Exchange strategy in the U.S. [1][2] - The subsidiary has officially initiated the application process for a stablecoin license with relevant U.S. regulatory bodies, demonstrating the company's commitment to global compliance and proactive strategy execution [2][3]. - The IVDNewCo Exchange ecosystem plan will be implemented in the U.S., including the creation of a tokenization platform for real-world assets based on medical innovation drug assets and establishing compliant financial infrastructure for the issuance, trading, and clearing of the IVDD stablecoin [2][3]. Group 2: Market Positioning - The company aims to become the first compliant trading platform focused on medical innovation drug RWA, leveraging its commercial network covering 1,674 tertiary hospitals in China and its capability to acquire quality NewCo assets globally [3]. - The strategic acceleration in the U.S. marks the transition of the company's "NewCo + RWA + stablecoin" strategy into a phase of large-scale implementation, positioning it to participate in the trillion-dollar compliant stablecoin market [3].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 對 因 本 公 告全部或任何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何 責 任。 IVD Medical Holding Limited 華檢醫療控股有限公司 （於 開 曼 群 島 註 冊 成 立 之 有 限 公 司） （股 份 代 號：1931） 自願性公告 美國穩定幣牌照申請及 IVDNewCo Exchange生態落地正式開啓 本 公 告 由 華 檢 醫 療 控 股 有 限 公 司（「本公司」，連 同 其 附 屬 公 司 統 稱「本集團」） 自 願 作 出。本 公 告 旨 在 進 一 步 更 新 本 公 司 於 二 零 二 五 年 七 月 十 七 日 發 布 之 自 願 性 公 告（「前次公告」）所 披 露 的 戰 略 舉 措 進 展，並 向 股 東 及 潛 在 投 資 者 提 供 本 集 團 業 務 發 展 之 資 料。除 非 文 義 另 有 所 指，否 則 本 公 告 所 用 詞 彙 與 前 次 公 告 所 界 定 者 ...

Core Viewpoint - The recent approval of the Stablecoin Bill by the Hong Kong Legislative Council aims to establish a licensing system for fiat-backed stablecoin issuers, enhancing regulatory clarity and support for the virtual asset ecosystem. Group 1: Regulatory Environment - The global regulatory stance is shifting, with the U.S. gradually loosening its pilot policies on stablecoins, allowing certain states to operate ahead of broader regulations. Hong Kong has also announced plans to regulate three categories of stablecoins, supporting and standardizing the virtual asset ecosystem [4]. - The regulatory landscape is evolving, with Hong Kong's Monetary Authority and U.S. regulators receiving stablecoin applications from Huajian Medical, positioning the company to capitalize on regulatory opportunities [3]. Group 2: Business Model and Growth Potential - The success of integrating stablecoin structures with real-world asset (RWA) medical assets will determine Huajian Medical's transition from a "medical service exporter" to a "medical fintech platform." If successful, it could become the first Hong Kong-listed company to achieve a true "medical RWA + Web3" closed loop [2]. - The dual licensing path is significant as it not only provides a channel for token issuance but also serves as a crucial bridge for global capital to enter the medical RWA market. This dual license can enhance multi-market payment connectivity and credibility [5]. Group 3: Strategic Partnerships - International partners are more inclined to engage with platforms that possess regulatory licenses. Huajian Medical is planning to introduce compliant structured financing tools and design different channels for U.S. and Hong Kong fund clients [6].